The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease
Biomolecules · 2023
DOI: 10.3390/biom13091303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Alexandra Albus und 7 weiteren Autor:innen. Beteiligte Einrichtung: Therapy Research in Neurogeriatrics, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, University Hospital Essen…. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation, University of Duisburg-Essen.
Abstract (Originalsprache)
The accumulation and aggregation of alpha-synuclein (α-Syn) are pathological processes associated with Parkinson’s disease, indicating that the regulation of protein is a crucial etiopathological mechanism. Interestingly, human serum and cerebrospinal fluid contain autoantibodies that recognize α-Syn. This potentially demonstrates an already existing, naturally decomposing, and protective system. Thus, quantitative or qualitative alterations, such as the modified antigen binding of so-called naturally occurring autoantibodies against α-Syn (nAbs-α-Syn), may induce disease onset and/or progression. We investigated the serum titers and binding characteristics of nAbs-α-Syn in patients suffering from sporadic Parkinson’s disease (n = 38), LRRK2 mutation carriers (n = 25), and healthy controls (n = 22).
Methods
Titers of nAbs-α-Syn were assessed with ELISA and binding affinities and kinetics with SPR. Within the patient cohort, we discriminated between idiopathic and genetic (LRRK2-mutated) variants.
Results
ELISA experiments revealed no significant differences in nAbs-α-Syn serum titers among the three cohorts. Moreover, the α-Syn avidity of nAbs-α-Syn was also unchanged.
Conclusions
Our findings indicate that nAbs-α-Syn concentrations or affinities in healthy and diseased persons do not differ, independent of mutations in LRRK2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Therapy Research in Neurogeriatrics, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, University Hospital Essen, 45147 Essen, Germany.
- Department for Neurology, Philipps-University Marburg, 35037 Marburg, Germany.
- Department of Chemistry and Biology, Fresenius University of Applied Sciences, 65510 Idstein, Germany.
- Faculty of Statistics, TU Dortmund University, 44227 Dortmund, Germany.
- Institute of Physical Biology, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
- Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum Jülich, 52428 Jülich, Germany.
ORCID-Profile: Alexandra Albus, Dieter Willbold, Jean Alexander Ross
Förderung
- Michael J. Fox Foundation
- University of Duisburg-Essen
Zitieren
APA
Albus, A., Kronimus, Y., Burg-Roderfeld, M., van der Wurp, H., Willbold, D., Ziehm, T., Dodel, R., & Ross, J. A. (2023). The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease. Biomolecules. https://doi.org/10.3390/biom13091303
Vancouver
Albus A, Kronimus Y, Burg-Roderfeld M, van der Wurp H, Willbold D, Ziehm T, et al. The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease. Biomolecules. 2023. doi:10.3390/biom13091303
BibTeX
@article{Albus2023,
author = {Albus, Alexandra and Kronimus, Yannick and Burg-Roderfeld, Monika and van der Wurp, Hendrik and Willbold, Dieter and Ziehm, Tamar and Dodel, Richard and Ross, Jean Alexander},
title = {The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13091303}
}
EUVIMED